MedTrace Logo

A Study of GC1111 in Hunter Syndrom Patients

NCT03920540 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2024-04-16

No results posted yet for this study

Summary

The objective of this study is to evaluate the efficacy of GC1111 in Hunter Syndrome Patients

Conditions

Interventions

COMBINATION_PRODUCT

GC1111

GC1111 is 0.5mg per kg of body weight once weekly to be administered slowly by intravenous infusion.

COMBINATION_PRODUCT

Comparator

Comparator is 0.5mg per kg of body weight once weekly to be administered slowly by intravenous infusion.

Sponsors & Collaborators

  • Green Cross Corporation

    lead INDUSTRY

Principal Investigators

  • DongKyu Jin, M.D., Ph.D. · Samsung Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
5 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-09
Primary Completion
2022-02-15
Completion
2022-02-15

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03920540 on ClinicalTrials.gov